2020 Q1 Form 10-Q Financial Statement
#000143774920010514 Filed on May 13, 2020
Income Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $2.000M | $2.610M |
| YoY Change | -23.37% | 86.43% |
| % of Gross Profit | ||
| Research & Development | $938.6K | $1.451M |
| YoY Change | -35.32% | 208.13% |
| % of Gross Profit | ||
| Depreciation & Amortization | $12.33K | $13.98K |
| YoY Change | -11.85% | 77.81% |
| % of Gross Profit | ||
| Operating Expenses | $2.937M | $4.064M |
| YoY Change | -27.74% | 116.83% |
| Operating Profit | -$2.937M | -$4.064M |
| YoY Change | -27.74% | 116.83% |
| Interest Expense | ||
| YoY Change | ||
| % of Operating Profit | ||
| Other Income/Expense, Net | -$10.41K | -$8.978K |
| YoY Change | 15.96% | -15316.95% |
| Pretax Income | -$2.947M | -$4.073M |
| YoY Change | -27.64% | 117.31% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$2.947M | -$4.073M |
| YoY Change | -27.64% | 117.31% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$323.1K | -$619.5K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 9.131M | 9.116M |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $9.400M | $19.60M |
| YoY Change | -52.04% | 308.33% |
| Cash & Equivalents | $9.351M | $19.57M |
| Short-Term Investments | ||
| Other Short-Term Assets | $134.5K | $27.96K |
| YoY Change | 381.16% | -95.34% |
| Inventory | ||
| Prepaid Expenses | $1.337M | $835.5K |
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $11.67M | $20.78M |
| YoY Change | -43.85% | 264.55% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $29.73K | $48.21K |
| YoY Change | -38.33% | -51.79% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $17.22K | $17.22K |
| YoY Change | 0.0% | -82.78% |
| Total Long-Term Assets | $145.2K | $245.2K |
| YoY Change | -40.79% | -18.27% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $11.67M | $20.78M |
| Total Long-Term Assets | $145.2K | $245.2K |
| Total Assets | $11.81M | $21.02M |
| YoY Change | -43.82% | 250.41% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $356.3K | $464.0K |
| YoY Change | -23.22% | 131.99% |
| Accrued Expenses | $52.47K | $74.84K |
| YoY Change | -29.89% | -85.03% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $908.0K | $1.491M |
| YoY Change | -39.11% | 113.02% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $0.00 | $0.00 |
| YoY Change | ||
| Total Long-Term Liabilities | $0.00 | $0.00 |
| YoY Change | ||
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $908.0K | $1.491M |
| Total Long-Term Liabilities | $0.00 | $0.00 |
| Total Liabilities | $916.0K | $1.529M |
| YoY Change | -40.08% | 118.36% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$97.02M | -$80.90M |
| YoY Change | 19.92% | |
| Common Stock | $107.2M | $99.70M |
| YoY Change | 7.57% | |
| Preferred Stock | $671.0K | $702.0K |
| YoY Change | -4.42% | |
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $10.90M | $19.50M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $11.81M | $21.02M |
| YoY Change | -43.82% | 250.41% |
Cashflow Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$2.947M | -$4.073M |
| YoY Change | -27.64% | 117.31% |
| Depreciation, Depletion And Amortization | $12.33K | $13.98K |
| YoY Change | -11.85% | 77.81% |
| Cash From Operating Activities | -$3.230M | -$2.149M |
| YoY Change | 50.31% | -9.97% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | ||
| YoY Change | ||
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | |
| YoY Change | ||
| Cash From Investing Activities | ||
| YoY Change | ||
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 11.34M | |
| YoY Change | ||
| NET CHANGE | ||
| Cash From Operating Activities | -3.230M | -2.149M |
| Cash From Investing Activities | ||
| Cash From Financing Activities | 11.34M | |
| Net Change In Cash | -3.230M | 9.188M |
| YoY Change | -135.16% | -476.86% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$3.230M | -$2.149M |
| Capital Expenditures | ||
| Free Cash Flow | -$2.149M | |
| YoY Change | -11.85% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q1 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
83071 | |
| CY2019Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
82536 | |
| CY2019Q1 | atos |
Adjustments To Additional Paid In Capital Transfer Of Stockbased Compensation Liability Upon Option Cancellation
AdjustmentsToAdditionalPaidInCapitalTransferOfStockbasedCompensationLiabilityUponOptionCancellation
|
3151944 | |
| CY2019Q1 | atos |
Adjustments To Additional Paid In Capital Transfer Of Stockbased Compensation Liability Upon Option Cancellation
AdjustmentsToAdditionalPaidInCapitalTransferOfStockbasedCompensationLiabilityUponOptionCancellation
|
3151944 | |
| CY2020Q1 | atos |
Change In Stock Based Compensation Liability
ChangeInStockBasedCompensationLiability
|
||
| CY2019Q1 | atos |
Change In Stock Based Compensation Liability
ChangeInStockBasedCompensationLiability
|
1741919 | |
| CY2019Q1 | atos |
Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
|
2800000 | |
| CY2020Q1 | atos |
Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
|
-5316 | |
| CY2019Q1 | atos |
Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
|
-280242 | |
| CY2020Q1 | atos |
Number Of Shares Authorized To Issue
NumberOfSharesAuthorizedToIssue
|
185000000 | |
| CY2020Q1 | atos |
Prepaid Financial Exchange Fees Current
PrepaidFinancialExchangeFeesCurrent
|
32250 | |
| CY2019Q4 | atos |
Prepaid Financial Exchange Fees Current
PrepaidFinancialExchangeFeesCurrent
|
||
| CY2020Q1 | atos |
Professional Services Current
ProfessionalServicesCurrent
|
278298 | |
| CY2019Q4 | atos |
Professional Services Current
ProfessionalServicesCurrent
|
108850 | |
| CY2020Q1 | atos |
Reclassification Of Stock Based Liability Awards To Equity Upon Cancellation
ReclassificationOfStockBasedLiabilityAwardsToEquityUponCancellation
|
||
| CY2019Q1 | atos |
Reclassification Of Stock Based Liability Awards To Equity Upon Cancellation
ReclassificationOfStockBasedLiabilityAwardsToEquityUponCancellation
|
3151944 | |
| CY2020Q1 | atos |
Research And Development Current
ResearchAndDevelopmentCurrent
|
712387 | |
| CY2019Q4 | atos |
Research And Development Current
ResearchAndDevelopmentCurrent
|
507733 | |
| CY2020Q1 | atos |
Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
|
734340 | |
| CY2019Q4 | atos |
Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
|
739656 | |
| CY2019Q1 | atos |
Stock Issued During Period Shares Warrant Exercised
StockIssuedDuringPeriodSharesWarrantExercised
|
2800000 | |
| CY2019Q1 | atos |
Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
|
11336710 | |
| CY2020Q1 | atos |
Working Capital
WorkingCapital
|
10800000 | |
| CY2020Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
356252 | |
| CY2019Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
293171 | |
| CY2020Q1 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
203779 | |
| CY2019Q4 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
646064 | |
| CY2019Q4 | us-gaap |
Accrued Income Taxes
AccruedIncomeTaxes
|
0 | |
| CY2020Q1 | us-gaap |
Accrued Income Taxes
AccruedIncomeTaxes
|
0 | |
| CY2020Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
52474 | |
| CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
77888 | |
| CY2020Q1 | us-gaap |
Accrued Vacation Current
AccruedVacationCurrent
|
179533 | |
| CY2019Q4 | us-gaap |
Accrued Vacation Current
AccruedVacationCurrent
|
170820 | |
| CY2020Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
105600232 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
9130984 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
9130984 | |
| CY2020Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
1643565 | |
| CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
1643565 | |
| CY2019Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
104912480 | |
| CY2020Q1 | us-gaap |
Additional Paid In Capital Preferred Stock
AdditionalPaidInCapitalPreferredStock
|
670999 | |
| CY2019Q4 | us-gaap |
Additional Paid In Capital Preferred Stock
AdditionalPaidInCapitalPreferredStock
|
670999 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
275833 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
687752 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
687752 | |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
275833 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5569028 | |
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4611845 | |
| CY2020Q1 | us-gaap |
Assets
Assets
|
11812302 | |
| CY2019Q4 | us-gaap |
Assets
Assets
|
14489855 | |
| CY2020Q1 | us-gaap |
Assets Current
AssetsCurrent
|
11667120 | |
| CY2019Q4 | us-gaap |
Assets Current
AssetsCurrent
|
14319266 | |
| CY2020Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
9351141 | |
| CY2019Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
19568247 | |
| CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
12581136 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
12691136 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
10490493 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
9461141 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
19678247 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-3229995 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
9187754 | |
| CY2020Q1 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
8967650 | |
| CY2019Q4 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
12316429 | |
| CY2020Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.18 | |
| CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.18 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
175000000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
175000000 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
9130984 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
9130984 | |
| CY2020Q1 | us-gaap |
Deposit Assets
DepositAssets
|
14218 | |
| CY2019Q4 | us-gaap |
Deposit Assets
DepositAssets
|
14218 | |
| CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
12326 | |
| CY2019Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
13983 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.32 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.62 | |
| CY2020Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
466383 | |
| CY2019Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
899420 | |
| CY2020Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
60833 | |
| CY2019Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
68542 | |
| CY2020Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1998389 | |
| CY2019Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2613093 | |
| CY2020Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-2947420 | |
| CY2019Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-4073307 | |
| CY2020Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
||
| CY2019Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
||
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
63081 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
110642 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-25414 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-102230 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-433037 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-43312 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
108389 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-2985 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
-9434 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
-30076 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
474776 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
325635 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
12400 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
29500 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
4500 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
12900 | |
| CY2020Q1 | us-gaap |
Liabilities
Liabilities
|
915965 | |
| CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
1333850 | |
| CY2020Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
11812302 | |
| CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
14489855 | |
| CY2020Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
907952 | |
| CY2019Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1322742 | |
| CY2020Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font: inherit;">1:</div> NATURE OF OPERATIONS</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> January 6, 2020, </div>we changed our corporate name from Atossa Genetics Inc. to Atossa Therapeutics, Inc.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Atossa Therapeutics, Inc. (the “Company”) was incorporated on <div style="display: inline; font-style: italic; font: inherit;"> April 30, 2009, </div>in the State of Delaware. The Company was initially formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company’s fiscal year ends on <div style="display: inline; font-style: italic; font: inherit;"> December 31. </div>The Company is currently focused on development of its pharmaceutical and drug delivery programs for the treatment of the Novel Coronavirus ("COVID-<div style="display: inline; font-style: italic; font: inherit;">19"</div>), breast cancer and other breast conditions.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 21.45pt 0pt -9pt; text-align: justify; text-indent: 18pt;"><div style="display: inline; font-weight: bold;">Impact of the Novel Coronavirus </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: -9pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The continued spread of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic is affecting the United States and global economies and <div style="display: inline; font-style: italic; font: inherit;"> may </div>affect the Company’s operations and those of <div style="display: inline; font-style: italic; font: inherit;">third</div> parties on which the Company relies, including causing possible disruptions in the supply of the Company’s Endoxifen, AT-<div style="display: inline; font-style: italic; font: inherit;">H201</div> and the conduct of current and future clinical trials. In addition, the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic <div style="display: inline; font-style: italic; font: inherit;"> may </div>affect the operations of the U.S. Food and Drug Administration and other health authorities including similar entities/agencies in Sweden and Australia, which could result in delays in meetings, reviews and approvals. The evolving COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic could also directly or indirectly impact the pace of enrollment in the Company’s clinical trials for at least the next several months and possibly longer as patients <div style="display: inline; font-style: italic; font: inherit;"> may </div>avoid or <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be able to travel to healthcare facilities and physicians’ offices except for a health emergency. Such facilities and offices <div style="display: inline; font-style: italic; font: inherit;"> may </div>also be required to focus limited resources on non-clinical trial activities, including treatment of COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> patients, and <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be available, in whole or in part, for clinical trial activities related to Endoxifen. Additionally, while the potential economic impact brought by, and the duration of, the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic is difficult to assess or predict, the impact of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic on the global financial markets <div style="display: inline; font-style: italic; font: inherit;"> may </div>reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic is highly uncertain and subject to change. The Company does <div style="display: inline; font-style: italic; font: inherit;">not</div> yet know the full extent of potential delays or impacts on its business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material adverse impact on the Company’s liquidity, capital resources, operations, financial position and business and those of the <div style="display: inline; font-style: italic; font: inherit;">third</div> parties on which we rely.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:22.5pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">In response to the Coronavirus pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on <div style="display: inline; font-style: italic; font: inherit;"> March 27, 2020. </div>The CARES Act, among other things, includes provisions related to refundable payroll tax credits, deferment of employer side social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act had <div style="display: inline; font-style: italic; font: inherit;">no</div> material impact on the Company’s income tax provision for the <div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020. </div>The Company continues to examine the elements of the CARES Act and the impact it <div style="display: inline; font-style: italic; font: inherit;"> may </div>have on its financial position, results of operations and cash flows.</div></div> | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
||
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
11336710 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
||
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
||
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-3229995 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2148956 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2947420 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4073307 | |
| CY2020Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-2947420 | |
| CY2019Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-4073307 | |
| CY2020Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
2937009 | |
| CY2019Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
4064329 | |
| CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2937009 | |
| CY2019Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4064329 | |
| CY2020Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
13300 | |
| CY2019Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
12900 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
29385 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
39371 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
8013 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
11108 | |
| CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
14700 | |
| CY2019Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
14600 | |
| CY2020Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
37397 | |
| CY2019Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
50479 | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.12 | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P270D | |
| CY2020Q1 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
134519 | |
| CY2019Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
26130 | |
| CY2020Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
17218 | |
| CY2019Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
17218 | |
| CY2020Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
3458 | |
| CY2019Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
12892 | |
| CY2020Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-10411 | |
| CY2019Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-8978 | |
| CY2020Q1 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
1917 | |
| CY2019Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
4792 | |
| CY2020Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2020Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2020Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
671 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
671 | |
| CY2020Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
671 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
671 | |
| CY2020Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
1 | |
| CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
1 | |
| CY2020Q1 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1337120 | |
| CY2019Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
862344 | |
| CY2020Q1 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
280098 | |
| CY2019Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
222476 | |
| CY2020Q1 | us-gaap |
Prepaid Rent
PrepaidRent
|
17952 | |
| CY2019Q4 | us-gaap |
Prepaid Rent
PrepaidRent
|
4275 | |
| CY2020Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
0 | |
| CY2019Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
11300000 | |
| CY2019Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
11336710 | |
| CY2020Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
29734 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
34350 | |
| CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
938620 | |
| CY2019Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1451236 | |
| CY2019Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
110000 | |
| CY2020Q1 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
110000 | |
| CY2019Q1 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
110000 | |
| CY2020Q1 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
110000 | |
| CY2019Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
110000 | |
| CY2020Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-97018460 | |
| CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-94071040 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
||
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
||
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
||
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
||
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
||
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
||
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
||
| CY2020Q1 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
687752 | |
| CY2019Q1 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
275833 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8805010 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
19496190 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
13156005 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
10896337 | |
| CY2020Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Use of Estimates:</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div></div> | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
9130984 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
6565514 |
